AI-Enhanced Lipo-Glycopeptide Cleavable Derivatives for Targeted Gram-Positive Bacterial Infection Treatment
Legal Citation
Summary of the Inventive Concept
This inventive concept integrates lipo-glycopeptide cleavable derivatives with AI, IoT, blockchain, and new materials to create a more powerful system for targeted Gram-positive bacterial infection treatment.
Background and Problem Solved
The original patent disclosed lipo-glycopeptide cleavable derivatives for treating Gram-positive bacterial infections. However, these derivatives had limitations in terms of diagnostic accuracy, supply chain security, and treatment efficacy. This new inventive concept addresses these limitations by incorporating synergistic technologies.
Detailed Description of the Inventive Concept
The system comprises a lipo-glycopeptide cleavable derivative administered via a nebulizer or dry powder inhaler, an AI-powered diagnostic module for real-time infection clearance feedback, a blockchain-secured supply chain for tracking origin and authenticity, and a composition with a new material exhibiting antimicrobial properties. The IoT-enabled sensor tracks patient health metrics, and the AI-powered analytics module identifies trends and optimizes treatment regimens. Machine learning algorithms are used to predict the optimal dosage for each patient.
Novelty and Inventive Step
The new claims introduce the innovative integration of AI, IoT, blockchain, and new materials with lipo-glycopeptide cleavable derivatives, providing a synergistic system that overcomes the limitations of the original patent.
Alternative Embodiments and Variations
Alternative embodiments may include using different AI algorithms, incorporating additional sensors or diagnostic tools, or modifying the composition of the new material. Variations may include adapting the system for treating different types of infections or using different administration routes.
Potential Commercial Applications and Market
This inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the development of targeted treatments for Gram-positive bacterial infections. The system's enhanced diagnostic accuracy, supply chain security, and treatment efficacy make it an attractive solution for hospitals, clinics, and patients.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K38/14 |
| A | A61 | A61K9/008 |
| A | A61 | A61K9/0073 |
| A | A61 | A61K9/0075 |
| A | A61 | A61P31/04 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical biotechnology, specifically antimicrobial drug delivery and treatment of Gram-positive bacterial infections, with expertise in drug formulation, diagnostic technologies, and advanced drug administration methods
Person of Ordinary Skill (PHOSITA) Profile
A researcher or pharmaceutical scientist with advanced degrees in microbiology or pharmaceutical sciences, experienced in drug delivery systems, bacterial infection treatment, and emerging medical technologies, familiar with interdisciplinary approaches to medical innovation
Obviousness Rationale
A PHOSITA would recognize that integrating AI, IoT, and blockchain technologies with existing lipo-glycopeptide delivery methods represents a predictable extension of known pharmaceutical innovation strategies. The core therapeutic mechanism remains consistent with the source patent, while the added technological layers provide enhanced monitoring and optimization capabilities. These technological integrations would be considered routine application of known techniques to improve drug delivery and treatment efficacy.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,597 |
|---|---|
| Title | Lipo-glycopeptide cleavable derivatives and uses thereof |
| Assignee(s) | Insmed Incorporated |